The evolution from an “average” study patient to patient-specific characteristics to guide interventions in vascular medicine by Podlasek, Anna et al.
                                                                    
University of Dundee
The evolution from an “average” study patient to patient-specific characteristics to
guide interventions in vascular medicine
Podlasek, Anna; Grunwald, Iris Q.; Musiaek, Piotr
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Podlasek, A., Grunwald, I. Q., & Musiaek, P. (2021). The evolution from an “average” study patient to patient-
specific characteristics to guide interventions in vascular medicine. Polish Archives of Internal Medicine, 131(1),
5-8. https://doi.org/10.20452/pamw.15791
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 27. Apr. 2021
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survivors are left with major mental and physi‑
cal disability. The consequences are detrimental 
not only for the patient but also for the families, 
the healthcare system, and society. Large ‑scale ef‑
forts are needed to maximize preventive rather 
than reactive treatment strategies. Atherosclerot‑
ic carotid disease is responsible for a much great‑
er proportion of strokes than just those present‑
ing with tandem occlusion of the intra‑ and ex‑
tracranial vessels (approximately 20%). It is also 
the underlying cause for hemodynamic strokes 
due to a high ‑grade carotid stenosis. In addition, 
showers of emboli from a “hot” carotid plaque can 
cause severe strokes, even in the absence of large 
vessel occlusion.
After detection of a clinically “asymptomatic” 
carotid stenosis (that may in reality not be truly 
asymptomatic, as symptoms may not be appar‑
ent during clinical examinations while cerebral 
imaging may show signs of ipsilateral ischemic 
damage), clinicians have to answer the 2 funda‑
mental questions: 1) what is the risk of the par‑
ticular carotid lesion to cause stroke, distal em‑
boli, or underperfusion? and 2) what is the bal‑
ance of risks and benefits of an intervention in 
the context of the individual patient, taking into 
account clinical, physiological, imaging, and le‑
sion characteristics (FIguRE 1).
Ideally, indicators that would put the indi‑
vidual at a greater risk for an impending stroke 
should be identified before the stroke disaster oc‑
curs. The treatment should be preventive rather 
than reactive and should be safe and long ‑term 
effective.2,4
It is clear today that optimized medical ther‑
apy, although it may reduce or delay stroke risk, 
It’s about integrating individual clinical expertise 
and the best external evidence
Sackett DL, Rosenberg WM, Gray JA, et al. Evidence‑
‑based medicine: what it is and what it isn’t. BMJ. 
1996; 312: 71.
There is false optimism today that cardiovascu‑
lar disease is no longer a major public health prob‑
lem. Quite the opposite: despite the unquestion‑
able progress in cardiovascular pharmacothera‑
py and prevention, the burden of cardiovascular 
disease is increasing.1 Over the next 20 years at 
least, ischemic heart disease and stroke will remain 
the top causes of death and premature death and 
will continue as the largest disease burden in Eu‑
rope, with stroke as the number 1 cause for disabili‑
ty.1 Nowadays, strokes are, in their substantial pro‑
portion, preventable2 and educated efforts are ur‑
gently needed to reduce this proportion.1 The im‑
plementation of existing knowledge is essential to 
reduce the number of strokes, but it is not suffi‑
cient.1 Approaches for early disease detection need 
to be paired with further insights into disease mech‑
anisms, taking advantage of novel technologies, in‑
cluding new biomarkers, imaging and “big” data in 
risk stratification.1,3 It becomes fundamental today 
to understand individual variations in disease pa‑
thology and the risk of symptom occurrence.3 Safe 
and more efficacious treatments, regarding both 
pharmacotherapy and devices, need to be applied 
on a patient ‑specific basis—to precisely target and 
modify the disease ‑related risks.1
Stroke is one of the most dreaded events in 
life. Over 80% of strokes occur without any clin‑
ical warning. A substantial proportion of stroke 
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in clinical practice or may be as rare as the tip of 
the Gaussian distribution. Today, more a precise 
disease classification and greater understand‑
ing of individual variations in disease patholo‑
gy drive the development of targeted therapeu‑
tics.3 There is increasing understanding in vas‑
cular medicine that patient and disease char‑
acteristics matter—both in the clinical risks in 
relation to the disease and in response to treat‑
ment. Interventions presumed to be “futile” on 
the basis of an “average patient” response in 
studies with a substantial selection bias—or in 
studies that have enrolled unnaturally homoge‑
nous populations—may actually work very well 
for other patients with the disease.
Today, there is increasing evidence that the ca‑
rotid plaque (along with the “vulnerable blood” 
properties) itself plays an important, mechanis‑
tic part in transforming a lesion from asymptom‑
atic to symptomatic.5,6,9,10 Individual patient, le‑
sion and disease characteristics form the very ba‑
sis of contemporary clinical decision ‑making in 
atherosclerotic carotid stenosis (FIguRE 1), consis‑
tent with the EBM original principle of integrat‑
ing individual clinical expertise and the best ex‑
ternal evidence.
In this issue of Polish Archives of Internal Med-
icine (Pol Arch Intern Med), a multispecialty team 
of stroke neurologists, angiologists, and vascu‑
lar surgeons share with us their identification 
of clinical and imaging factors associated with 
the symptomatic status of carotid artery steno‑
sis.11 This work, although it may lack the preci‑
sion of plaque characteristics used in some oth‑
er recent studies,5,6,9,12 is focused on very prac‑
tical aspects of decision making.11 It thus adds 
importantly to the currently “hot” topic of an‑
swering the unmet need for risk stratification 
in clinically asymptomatic carotid artery steno‑
sis,5,6,9,10,12 bearing in mind that what is not (for 
some individuals—not yet) manifested clinically 
may be already manifested on cerebral imaging.
The field of carotid artery disease, in regard 
to risk / benefit stratification, is no exemption 
from other fields in vascular medicine. Recent‑
ly, another multispecialty work published in Pol 
Arch Intern Med13 identified several predictors of 
favorable clinical responses to the “condemned” 
treatment of renal artery stenosis revasculariza‑
tion. Identification of those patients with better 
blood pressure control and improved renal func‑
tion (or halted deterioration) as a result of renal 
artery revascularization may now enable target‑
ing the intervention to those who are likely to 
benefit from it.13 This is opposite to a simplistic 
“no intervention for anybody” approach—be‑
cause of the statistical lack of an “average” bene‑
fit that may well have been driven by largely re‑
cruiting patients with functionally insignificant 
stenoses and / or kidney failure already too ad‑
vanced to be reversible
The recent publications in the Pol Arch Intern 
Med11,13 are examples of work in progress that, 
ideally, requires further, prospective validation. 
does not sufficiently prevent strokes in relation 
to carotid stenosis.2,4 Pharmacologic treatment 
may modify stroke ‑prone “vulnerable” plaques 
and the “vulnerable blood” parameters insuffi‑
ciently to abolish the increased stroke risk.5,6 Pa‑
tients who develop symptoms or signs of cerebral 
damage whilst already on optimized medical ther‑
apy continue to join contemporary all ‑comer ca‑
rotid revascularization studies.2,4 Such patients 
should be revascularized before rather than in re‑
action to their irreversible cerebral neuronal loss 
and associated cognitive decline.
Evidence ‑based medicine (EBM) points ran‑
domized clinical trials (RCTs) as the gold stan‑
dard for demonstrating (or refuting) the bene‑
fits of a particular intervention. Yet, RCTs have 
important limitations of which 4 are particularly 
relevant today: 1) the null hypothesis (which pre‑
sumes that there is no difference between treat‑
ments); 2) probability (with a 5% threshold being 
generally used to evaluate the null hypothesis); 
3) generalizability (in clinical practice, the test‑
ed intervention is likely to be used in a far more 
heterogeneous population than the RCT popu‑
lation); and 4) resource implications (these are 
often prohibitively high limiting precise disease 
classifications with imaging, histological, clin‑
ical, and cognitive assessment data as well as 
an increasingly prohibitively high cost of con‑
ducting an RCT).7
The null hypothesis may be no longer relevant 
if there have been previous studies showing that 
a particular treatment has benefits in certain le‑
sion types or patient cohorts. This, indeed, has 
been the case with several recent RCTs in car‑
diovascular medicine, ie, regarding the fate of 
the thrombus extraction strategy in acute throm‑
botic coronary artery occlusions (patients with 
proximal thrombotic lesions were typically treat‑
ed outside randomization).
Randomizing patients who are a likely to ben‑
efit from an intervention is not ethical, because 
randomization requires uncertainty of the treat‑
ment effect. These patients typically receive in‑
tervention outside the RCT,8 and thus in many 
instances only those who are unlikely to benefit 
from the intervention get randomized.8 Indeed, 
today’s cardiovascular RCTs increasingly suffer 
from an “entry” bias that, in turn, substantial‑
ly affects generalization of results. Real ‑life all‑
‑comer studies and registries have greater rele‑
vance to clinical practice at large. All ‑comer reg‑
istries are (in contrast to RCTs) naturally het‑
erogeneous. They are thus more likely to identi‑
fy the individual characteristics of those who are 
at a greater risk of developing clinical consequenc‑
es of the pathology (if left untreated) or identify 
the responders to treatment.
So, EBM today is not just about RCTs. Inter‑
estingly, already at its roots, EBM defined it‑
self as being “about integrating individual clin‑
ical expertise and the best external evidence” 
rather than being a “cookbook” clinical medi‑
cine. The “average” RCT patient may not exist 
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and, more importantly, many of their patients 
from the stalemate of wrongly understanding 
EBM as the medicine of averages.
Rather than treating RCT “average patients”—
who all too often differ from real life—or other 
statistical averages, clinicians need to look at the 
individual patient and their specific risk profile. 
Implementing patient ‑specific characteristics11,13 
to guide interventions in vascular medicine re‑
mains fully within the framework of “integrat‑
ing individual clinical expertise and the best ex‑
ternal evidence.” Thus decision making that, in 
contemporary clinical practice, integrates pa‑
tient and lesion characteristics continues to be 
evidence ‑based.
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lesion characteristics, operator experience, and the patient’s medical condition and imaging 
data that include the presence of ipsilateral ischemic cerebral damage. The patient factors are 
at the basis of decision making. Note that the “wating for symptoms” strategy exposes 
individuals (in particular those with “increased risk” characteristics) to the clinical and social 
consequences of stroke (80% of strokes give no clinical warning). This has to be balanced 
against the risk of plaque sequestration that, with the new technologies, may be associated 
with a minimal risk and abolished postprocedural risks (and the procedure itself may be 
minimally invasive). Accumulating evidence shows that even the maximized and presently 
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artery disease—although it may reduce or delay stroke risk.
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